Corsica Health Review
Best for: patients who want a single platform offering both compounded and brand-name GLP-1 options with publicly-disclosed pricing for direct comparison
Corsica Health (joincorsica.com) is a LegitScript-approved telehealth platform offering both compounded GLP-1s and brand-name FDA-approved injections. Compounded semaglutide starts at $299/month; compounded tirzepatide starts at $399/month; brand-name Ozempic, Wegovy, and Mounjaro are listed at $1,499/month. Programs include provider consultation, ongoing care support, and a structured Assessment → Provider Review → Receive Medication flow. One of the few platforms publicly disclosing both compounded and brand-name pricing on the marketing site.
Medium confidence · Last verified 2026-05-09 via manual · How we verify provider data
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
The Bottom Line
Corsica Health is a solid telehealth option with balanced features and pricing.
Score Breakdown
Drugs Offered
Corsica Health prescribes the following GLP-1 medications. Tap a drug to read our clinical guide with FDA label info, dosing schedules, side effects, and trial data.
Pricing
| Dose | Form | Price/mo |
|---|---|---|
| Compounded semaglutide (starting) | compounded | $299 |
| Compounded tirzepatide (starting) | compounded | $399 |
| Brand-name Wegovy | brand | $1499 |
| Brand-name Ozempic | brand | $1499 |
| Brand-name Mounjaro | brand | $1499 |
✓ Pros
- •Public pricing disclosure for BOTH compounded and brand-name SKUs on marketing site — material YMYL transparency advantage vs peers
- •$299/month compounded semaglutide and $399/month compounded tirzepatide are in the median range for compounded telehealth
- •$1,499/month brand-name Wegovy/Ozempic/Mounjaro pricing is below typical retail cash-pay (~$1,300-$1,800)
- •LegitScript-approved seal displayed with verification link
- •Structured 3-step intake (Assessment → Provider Review → Receive Medication) clearly disclosed
✗ Cons
- •Specific legal entity name + state of incorporation NOT publicly disclosed on the home page
- •Pharmacy partners described as 'licensed compounding pharmacy' but specific name NOT disclosed
- •Per-state availability NOT enumerated publicly
- •Zepbound and Foundayo NOT mentioned in the brand-name lineup (only Wegovy/Ozempic/Mounjaro)
- •First-month promotional pricing NOT disclosed (assumed steady-state from day one)
- •Lab work inclusion NOT clearly disclosed in marketing copy
Ready to start with Corsica Health?
Starting at $299/month. See current pricing and start your free consultation.
Sources & methodology
Our Corsica Health review applies the same 6-dimension scoring framework we use for every provider. Pricing, FDA approval status, compounding rules, and clinical-trial efficacy claims are sourced from the primary regulatory and peer-reviewed literature below.
Sources & methodology — as of May 2026
- 1.Weight Loss Rankings — GLP-1 Pricing Index 2026 (our independent dataset)— WeightLossRankings.org.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
- 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 7.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 8.FDA — Ozempic (semaglutide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 9.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
- 10.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 11.FDA — Mounjaro (tirzepatide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 12.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Garvey WT et al.)— New England Journal of Medicine.PMID: 40334173.
Alternatives to Corsica Health
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
Frequently Asked Questions
Glossary references
Key terms in this article, linked to their canonical definitions.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Ready to start with Corsica Health?
Starting at $299/month. See current pricing and start your free consultation.